J. Sabari - NYU Sch Med | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 20 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

2MO Amivantamab Plus Chemotherapy Vs Chemotherapy As First-Line Treatment in EGFR Exon 20 Insertion-Mutated Advanced NSCLC: Analysis of Post-Progression Endpoints from PAPILLON

E. Felip,C.A. Shu, A. Aguilar, K-J. Tang,M.R. García Campelo, K-Y. Lee,A. Delmonte,J. Sabari,N. Girard,A.S. Mansfield, K. Park, C. Zhou,K. Xia, A. Bhattacharya, M. Wade,M. Baig,T. Agrawal,P. Mahadevia,R.E. Knoblauch,R.E. Sanborn

ESMO Open (2024)

引用0浏览0引用

5MO Effect of Amivantamab Dose Interruptions on Efficacy and Safety of First-Line Amivantamab Plus Lazertinib in EGFR-mutant Advanced NSCLC: Exploratory Analyses from the MARIPOSA Study

M.R. García Campelo,B.C. Cho,N. Girard, S. Lu, H. Yoshioka,J-S. Lee,S-H. Lee, B. Liu,M.A.N. Sendur,B. Besse,A. Spira,E. Felip, A. Aguilar,J. Sabari,S. Popat,P. Mahadevia, S. Sethi,J.M. Bauml, Y.V. Ostapenko

ESMO Open (2024)

引用0浏览0引用

7P Patient-relevant Endpoints from PAPILLON: Amivantamab Plus Chemotherapy Vs Chemotherapy As First-Line Treatment of EGFR Exon 20 Insertion-Mutated (ex20ins) Advanced NSCLC

L. Paz-Ares, R. Veillon, M. Majem, C. Zhou, K-J. Tang,S-W. Kim, G. Richardson,N. Girard,R.E. Sanborn,A.S. Mansfield, K. Park,J. Sermon,J. Schuchard, A. Bhattacharya,P. Lorenzini,M. Baig,T. Agrawal,R.E. Knoblauch, A. Ono,J. Sabari

ESMO Open (2024)

引用0浏览0引用

6MO Subcutaneous Amivantamab Administered Every 4 Weeks (Q4W) in Patients with Advanced Solid Malignancies: the Phase Ib PALOMA Study

N. Leighl,A.R. Minchom, K.H.H. Lee,M.G. Krebs,B.C. Cho, Y.J. Kim, M.L. Johnson,J. Sabari, B. Sanusi,A. Alhadab,N. Haddish-Berhane, D. Zemlickis, A. Mitselos, C. Collins,M. Baig,J.M. Bauml,R.E. Knoblauch,P. Hellemans,R.E. Sanborn

ESMO Open (2024)

引用0浏览0引用

30 Long-term Efficacy, Safety, and Predictors of Response to Amivantamab among Patients with Post-Platinum EGFR Ex20ins-mutated Advanced NSCLC

P. Garrido Lopez,N. Girard,B. C. Cho,J. Sabari,A. Spira,R. E. Sanborn,K. Goto,J. C-H. Yang,J. Curtin,X. Lyu, A. He,J. Penton, J. Edwards, G. Low Massin,K. Xia,M. Chioda,M. Thayu,R. E. Knoblauch,P. Mahadevia,N. Leighl

Journal of thoracic oncologyno. 4 (2023): S36-S37

引用0浏览0引用

EP12.01-38 Real-world Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib Stratified by EGFR Subtype

Y. Liu, J. Bi,A. Moreira,A. Chachoua,V. Velcheti, S. Lau,S. Punekar,J. Sabari,E. Shum

Journal of Thoracic Oncologyno. 11 (2023): S655-S656

引用0浏览0引用

27P Amivantamab Versus Alternative Real-World Anti-Cancer Therapies in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in the US and Europe

N. Girard,J. Wolf,T. M. Kim,N. Leighl,C. Knott, T. Li,J. Cabrieto,J. Diels,J. Sermon,P. Mahadevia,C. A. Schioppa,J. Sabari

Journal of thoracic oncologyno. 4 (2023): S56-S56

引用0浏览0引用

8MO Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency

P.A. Jänne,A. Spira,G.J. Riely,S. Gadgeel,R. Heist,S-H.I. Ou,M.L. Johnson,J. Sabari,K. Velastegui,J.G. Christensen, W. Yang,K. Anderes,R. Chao,C. Paweletz

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S41-S42

引用0浏览0引用

Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis

N. Girard,N. Leighl,Y. Ohe,T. M. Kim, L. Demirdjian,A. B. Bourla,A. Abdul Sultan,P. Mahadevia,J. M. Bauml,J. Sabari

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S51-S52

引用0浏览0引用

PP01.31 Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (Ex20ins)

J. Sabari,T.M. Kim,A. Spira,S.H. Lee,G.C. Chang,J.-Y. Shih,M.J. Hochmair,C.A. Schioppa,A. Panaccione,J.B. Rose,M. Chioda,P. Mahadevia,B.C. Cho

Journal of Thoracic Oncology（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn